First and only drug to significantly extend survival for patients with higher-risk MDS
First drug approved by FDA for treatment of all MDS risk categories
First drug to achieve a transfusion independence rate of greater than 40 percent across all MDS risk categories
First MDS drug approved with multiple routes of administration (SC and IV)
LONDON–(BUSINESS WIRE)–Aug. 13, 2008–Chi-X(R) Europe Limited,
operator of the first live, pan-European, equity multilateral trading
facility (MTF), today announced that it is successfully trading,
clearing and settling five of the top component stocks of the Austrian
ATX 20 index, and plans to introduce the remainder of the index’s
components later in the month. The first stocks […]
LONDON–(BUSINESS WIRE)–Aug. 12, 2008–Chi-X(R) Europe Limited,
operator of the first live, pan-European, equity multilateral trading
facility (MTF), today announced the appointment of Marye Humphery as
Non-Executive Director.
Commenting on the appointment, Peter Randall, CEO of Chi-X Europe
Limited, said: “We are delighted to welcome Marye as a Non-Executive
Director of Chi-X Europe. She […]
WESTPORT, Conn.–(BUSINESS WIRE)–Aug. 11, 2008–Terex Corporation
(NYSE: TEX) today announced that it has reached a definitive agreement
to acquire the port equipment businesses of Fantuzzi Industries
S.a.r.l. for total consideration of approximately EUR 215 million.
These businesses are global leaders in the design, manufacture, and
service of port equipment, with factories in Italy, Germany and China,
as […]
TBILISI, Georgia–(BUSINESS WIRE)–Aug. 11, 2008–In connection
with the recent events in Georgia, Nicholas Enukidze, Chairman of the
Supervisory Board of Bank of Georgia, (LSE:BGEO) (GSE:GEB), (the
“Bank”), Georgia’s leading universal bank, provided the following
update:
“The recent events have had limited impact on the Bank’s
operations. As a precautionary security measure six out […]
OXFORD, England–(BUSINESS WIRE)–Aug. 7, 2008–Sucampo Pharma
Europe, Ltd (SPE), a wholly owned subsidiary of Sucampo
Pharmaceuticals, Inc. (NASDAQ:SCMP), today announced it has appointed
David Dodds, MRPharmS, M.B.A., to the position of Commercial Director
of Europe. Mr. Dodds will be responsible for establishing Sucampo’s
European operations, management, business development and commercial
strategies.
“We welcome David […]
PARSIPPANY, N.J.–(BUSINESS WIRE)–Aug. 5, 2008–The Medicines
Company (NASDAQ: MDCO) today announced that it has acquired
German-based Curacyte Discovery GmbH and its lead compound, CU-2010,
which is being developed for the prevention of surgical blood loss.
CU-2010 is a small molecule serine protease inhibitor. In
preclinical studies, the compound has demonstrated a favorable
pharmacokinetic profile for the surgical setting with a rapid […]
Mirasol-Treated Fresh Frozen Plasma (FFP) Meets Council of Europe Guidelines (14th Edition) for Protein Content of FFP
MUNICH, Germany–(BUSINESS WIRE)–Aug. 5, 2008–Curacyte AG today
announced that it has sold its wholly owned subsidiary, Curacyte
Discovery GmbH based in Leipzig (Germany) to The Medicines Company
(NASDAQ: MDCO). Curacyte Discovery is engaged in the development of
synthetic serine protease inhibitors in the area of hemostasis and
anti-coagulation. Its rationally-designed lead development candidate,
CU-2010, is being developed […]
MUNICH, Germany–(BUSINESS WIRE)–Aug. 5, 2008–TVM Capital, a
major shareholder of Curacyte AG, is pleased that Curacyte Discovery
GmbH, a wholly owned subsidiary of Curacyte AG has been acquired by
The Medicines Company (NASDAQ: MDCO) with the intent to further
develop the compound CU-2010 for the prevention of blood loss during
surgery. This development will continue in […]